Want to see APRE full AI Analyst Report?
APRE Stock Chart & Stats
$0.95
<$0.01(0.16%)
At close: 4:00 PM EDT
$0.95
<$0.01(0.16%)
Day’s Range― - ―
52-Week Range$0.41 - $1.49
Previous Close$0.61
Volume18.33K
Average Volume (3M)223.59K
Market Cap
$6.46M
Enterprise Value$2.40M
Total Cash (Recent Filing)$41.23M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.21
Next Earnings
Nov 05, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding12,591,136
10 Day Avg. Volume141,725
30 Day Avg. Volume223,588
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap0.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-442.84
Enterprise Value/Ebitda-0.20
Forecast
1Y Price Target
$3.30Price Target Upside247.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Expanded Intellectual PropertyBroader patent protection can preserve exclusivity for key precision-oncology assets and strengthen Aprea’s negotiating position with potential partners. If clinical development succeeds, the longer protection period may support durable commercial opportunity and reduce near-term competitive substitution.
APR-1051 Clinical ProgressAccelerating enrollment and early clinical activity provide evidence that APR-1051 is advancing beyond a purely preclinical thesis. A manageable tolerability profile and planned combination studies could broaden its addressable cancer populations if later-stage results confirm benefit.
Liquidity And Debt PositionA debt-free balance sheet avoids interest burden and near-term lender pressure, while the reported cash position and runway support continued clinical execution. This gives management time to generate additional data and pursue partnerships before another financing may be required.
Bears Say
No Recurring Product RevenueThe absence of recurring product revenue means Aprea has not yet demonstrated a commercial engine capable of funding operations. Financial performance therefore remains dependent on clinical progress, licensing opportunities, or external financing rather than customer-driven cash generation.
Persistent Losses And Cash BurnOngoing operating and net losses are translating into substantial cash consumption, limiting financial self-sufficiency. Even with a positive runway outlook, continued development spending will progressively reduce liquidity unless clinical assets begin generating partnerships, milestones, or future sales.
Pipeline Concentration And Execution RiskPausing ATRN-119 monotherapy narrows the active development focus and increases reliance on APR-1051 to create meaningful pipeline value. Combination strategies may expand opportunity, but they also require additional studies and execution before they can offset the reduced monotherapy path.
Aprea Therapeutics News
APRE FAQ
What was Aprea Therapeutics Inc’s price range in the past 12 months?
Aprea Therapeutics Inc lowest stock price was $0.41 and its highest was $1.49 in the past 12 months.
What is Aprea Therapeutics Inc’s market cap?
Aprea Therapeutics Inc’s market cap is $6.46M.
When is Aprea Therapeutics Inc’s upcoming earnings report date?
Aprea Therapeutics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 8 days.
How were Aprea Therapeutics Inc’s earnings last quarter?
Aprea Therapeutics Inc released its earnings results on Aug 12, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.178 by $0.108.
Is Aprea Therapeutics Inc overvalued?
According to Wall Street analysts Aprea Therapeutics Inc’s price is currently Undervalued.
Does Aprea Therapeutics Inc pay dividends?
Aprea Therapeutics Inc does not currently pay dividends.
What is Aprea Therapeutics Inc’s EPS estimate?
Aprea Therapeutics Inc’s EPS estimate is -0.07.
How many shares outstanding does Aprea Therapeutics Inc have?
Aprea Therapeutics Inc has 12,591,136 shares outstanding.
What happened to Aprea Therapeutics Inc’s price movement after its last earnings report?
Aprea Therapeutics Inc reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.178. Following the earnings report the stock price went up 3.485%.
Which hedge fund is a major shareholder of Aprea Therapeutics Inc?
Currently, no hedge funds are holding shares in APRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aprea Therapeutics Inc
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
APRE Stock 12 Month Forecast
Average Price Target
$3.30
▲(247.37% Upside)
Technical Analysis
Ownership Overview
6.39% Insiders
0.84% Mutual Funds
16.16% Other Institutional Investors
76.21% Public Companies and
Individual Investors